Vivos Therapeutics Reports Growth Amid Strategic Changes
Vivos Therapeutics Delivers Financial Insights and Operational Strategy
LITTLETON, Colo. — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical device company at the forefront of sleep-related breathing disorders, has announced its financial results along with significant operational updates for the most recent quarter.
Kirk Huntsman, Chairman and CEO of Vivos, expressed the critical importance of the second quarter of 2025 for the company's trajectory. A major highlight was the successful acquisition of The Sleep Center of Nevada (SCN), marking a significant shift in Vivos' approach to sales and service delivery. This acquisition is critical as it transitions the model from relying solely on dental professionals to establishing direct relationships with patients, providing them with Vivos' advanced obstructive sleep apnea (OSA) treatments.
Huntsman explained that the aim behind this acquisition was to align Vivos more closely with the patients who need these treatments, aligning operational efficiencies while also diversifying revenue streams beyond traditional channels.
Financial Overview for Q2 2025
For the second quarter of 2025, Vivos reported revenues of $3.8 million, reflecting a decline from $4.1 million in the previous year, primarily attributed to shifts in their sales strategy. Similarly, the gross profit was reported at $2.1 million, down from $2.7 million year-over-year.
Key Financial Metrics
- Revenue: $3.8 million for Q2 2025 and $6.8 million for the first half of the year.
- Gross Profit: $2.1 million for Q2 2025, down from $2.7 million in Q2 2024.
- Operating Expenses: Increased to $7.0 million due to strategic investments and elevated operational costs.
- Operating Loss: Raised to $4.9 million for Q2 2025, from $1.9 million in the same period last year.
The increase in operating expenses is largely reflective of investments made in SCN, alongside anticipated non-recurring costs related to professional fees inherent in the acquisition process. As a growing medical technology provider, Vivos remains committed to enhancing its operational stability while adapting its adaptive market strategy.
New Operational Framework
In addition to SCN, Vivos is innovating its operational strategies by creating management agreements with sleep centers that may not be interested in acquisition but wish to implement Vivos' diagnostic and treatment methodologies. For example, an agreement established with MISleep Solutions LLC aims to provide cutting-edge OSA treatment options for patients in locations where traditional approaches were previously unaccessible.
These developments underscore Vivos’ commitment to expanding its influence in the sleep disorder sector by diversifying its partnerships and broadening the accessibility of its treatment solutions.
Investor Communications and Future Directions
The Company encourages stakeholders and interested parties to participate in its upcoming investor conference calls, where management will elaborate on these strategic initiatives and the anticipated impacts on revenue growth. For those unable to attend live, a replay will be made available shortly after the call concludes.
As Vivos positions itself for growth in the evolving landscape of sleep medicine, it emphasizes the importance of educating healthcare providers about the nuanced complexities of sleep health and the efficacy of its innovative treatments.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) has established itself as a leader in medical technology, specifically targeting the urgent need for effective treatments for sleep-related disorders. With proprietary devices cleared by the FDA for use in patients of all ages, Vivos is filled with potential as it takes strides to improve patient outcomes worldwide. By leveraging its groundbreaking Complete Airway Repositioning and Expansion (CARE) devices, Vivos presents non-invasive, nonsurgical treatments that alleviate symptoms associated with OSA, offering patients new hope for improved sleep health.
The company, founded in 2016 and headquartered in Littleton, CO, continues its mission to revolutionize the sector through innovation, strategic partnerships, and educational initiatives that empower every facet of the healthcare experience for OSA patients.
Frequently Asked Questions
What financial results did Vivos Therapeutics announce for Q2 2025?
Vivos reported revenues of $3.8 million, with a gross profit of $2.1 million, showing a decrease from the previous year.
What strategic changes has Vivos implemented in their operations?
The company shifted its model to directly engage patients by acquiring The Sleep Center of Nevada, enhancing its service delivery beyond dental providers.
How does Vivos plan to grow its market presence?
Vivos aims to expand through additional partnerships with sleep centers and innovative management agreements to reach more patients with their treatments.
What is Vivos’ approach towards OSA treatments?
The Vivos Method offers proprietary, clinically effective solutions that are both non-invasive and non-pharmaceutical, addressing the root causes of obstructive sleep apnea.
How can investors learn more about Vivos’ financial outlook?
Investors can join the company’s conference calls for updates, and replays will be available post-call for more details about financial performance and strategic initiatives.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
